Picard Medical Reports 11% Revenue Growth in Q3 2025, Faces Increased Operating Losses

Picard Medical, Inc. reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a total revenue of $3.93 million, an increase of 11% from $3.56 million in the same period of 2024. The growth was primarily driven by a 10% rise in product sales, which reached $3.86 million, and a notable increase in rental income. However, the company also faced a gross loss of $615,000, compared to a gross loss of $248,000 in the prior year, indicating rising costs associated with product manufacturing.

The company's operating expenses decreased slightly by 3% to $9.64 million for the nine months ended September 30, 2025, down from $9.89 million in the previous year. This reduction was attributed to lower research and development costs, which fell by 3%, and a decrease in selling, general, and administrative expenses. Despite these reductions, the overall operating loss widened to $10.25 million from $10.14 million year-over-year, largely due to a significant increase in other expenses, which surged by 498% to $12.43 million, primarily driven by derivative losses related to convertible notes.

In terms of strategic developments, Picard Medical completed its initial public offering (IPO) on September 2, 2025, raising approximately $17 million in gross proceeds. This capital infusion is expected to support the company's operations and growth initiatives. The IPO also facilitated the conversion of various convertible notes into common stock, significantly altering the company's capital structure. As of September 30, 2025, the company had 73.7 million shares of common stock outstanding, a substantial increase from the previous year.

Operationally, Picard Medical has made strides in expanding its market presence, particularly in the United States, which accounted for 90% of its revenue in the nine months ended September 30, 2025. The company has also been actively working on its product development roadmap, focusing on enhancing its SynCardia total artificial heart technology. The company has reported over 2,100 implants of its total artificial heart across 27 countries, underscoring its global reach and commitment to addressing advanced heart failure.

Looking ahead, Picard Medical anticipates continued operating losses as it invests in scaling its operations and developing next-generation products. The company has expressed the need for additional financing to support its growth strategy, emphasizing the importance of securing capital to maintain operations and achieve profitability. The management has acknowledged substantial doubt regarding the company's ability to continue as a going concern without further funding, highlighting the critical nature of its financial strategy moving forward.